Search Results - "Braybrooke, J. P."

The South West Area Mesothelioma and Pemetrexed trial: a multicentre prospective observational study evaluating novel markers of chemotherapy response and prognostication by Hooper, C E, Lyburn, I D, Searle, J, Darby, M, Hall, T, Hall, D, Morley, A, White, P, Rahman, N M, De Winton, E, Clive, A, Masani, V, Arnold, D T, Dangoor, A, Guglani, S, Jankowska, P, Lowndes, S A, Harvey, J E, Braybrooke, J P, Maskell, N A

“…Background: Robust markers that predict prognosis and detect early treatment response in malignant pleural mesothelioma (MPM) would enhance patient care…”
Get full text

Phase I and Pharmacokinetic Study of PKC412, an Inhibitor of Protein Kinase C by PROPPER, D. J, MCDONALD, A. C, KAYE, S. B, GANESAN, T. S, TALBOT, D. C, HARRIS, A. L, TWELVES, C, MAN, A, THAVASU, P, BALKWILL, F, BRAYBROOKE, J. P, CAPONIGRO, F, GRAF, P, DUTREIX, C, BLACKIE, R

“…N-Benzoyl staurosporine (PKC412) is a protein kinase C inhibitor with antitumor activity in laboratory models. We determined the toxicity of oral PKC412…”
Get full text

Patients' experiences following breast cancer treatment: an exploratory survey of personal and work experiences of breast cancer patients from three European countries by Braybrooke, J.P., Mimoun, S., Zarca, D., Elia, D., Pinder, B., Lloyd, A.J., Breheny, K., Lomazzi, M., Borisch, B.

“…Improved treatments for early breast cancer have led to a significant increase in overall survival. While evidence regarding potential long‐term sequelae of…”
Get full text

Trastuzumab Beyond Progression in Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: UK Practice now and in the Future by Robinson, T., Palmieri, C., Braybrooke, J.P.

Get full text

Treating Brain Metastases from Breast Cancer: Outcomes after Stereotactic Radiosurgery by Wilson, T.G., Robinson, T., MacFarlane, C., Spencer, T., Herbert, C., Wade, L., Reed, H., Braybrooke, J.P.

“…Stereotactic radiosurgery (SRS) is an alternative to surgery or whole brain radiotherapy for the control of single or multiple brain metastases in patients…”
Get full text

Is CBOP/BEP an alternative to BEP for patients with poor prognosis metastatic germ cell tumours? by Addeo, A, Fusco, V, Braybrooke, JP

Get full text

Comparison of prognostic factors in patients in phase I trials of cytotoxic drugs vs new noncytotoxic agents by HAN, C, BRAYBROOKE, J. P, DEPLANQUE, G, TAYLOR, M, MACKINTOSH, D, KAUR, K, SAMOURI, K, GANESAN, T. S, HARRIS, A. L, TALBOT, D. C

“…The aims of this study were to identify prognostic variables for toxicity and survival in patients with cancer participating in phase I clinical trials and…”
Get full text

A phase II study of bryostatin 1 in metastatic malignant melanoma by PROPPER, D. J, MACAULAY, V, O'BYRNE, K. J, BRAYBROOKE, J. P, WILNER, S. M, GANESAN, T. S, TALBOT, D. C, HARRIS, A. L

“…Bryostatin 1 is a protein kinase C partial agonist which has both antineoplastic and immune-stimulatory properties, including the induction of cytokine release…”
Get full text

Expert UK consensus on the definition of high risk of recurrence in HER2-negative early breast cancer: A modified Delphi panel by Copson, E.R., Abraham, J.E., Braybrooke, J.P., Cameron, D., McIntosh, S.A., Michie, C.O., Okines, A.F.C., Palmieri, C., Raja, F., Roylance, R., Spensley, S.

“…There is currently no standardised definition for patients at high risk of recurrence of human epidermal growth factor receptor 2 (HER2)-negative early breast…”
Get full text

Phase I Study of Intrapleural Batimastat (BB-94), a Matrix Metalloproteinase Inhibitor, in the Treatment of Malignant Pleural Effusions by MACAULAY, V. M, O'BYRNE, K. J, SAUNDERS, M. P, BRAYBROOKE, J. P, LONG, L, GLEESON, F, MASON, C. S, HARRIS, A. L, BROWN, P, TALBOT, D. C

“…Tumor cells and associated stromal cells secrete matrix metalloproteinases (MMPs), contributing to invasion, angiogenesis, and metastasis. Batimastat (BB-94)…”
Get full text

Pharmacokinetically guided phase I trial of topotecan and etoposide phosphate in recurrent ovarian cancer by LEVITT, N. C, PROPPER, D. J, GANESAN, T. S, MADHUSUDAN, S, BRAYBROOKE, J. P, ECHETA, C, TE POELE, R, DAVIES, S. L, FLANAGAN, E, HICKSON, I. D, JOEL, S

“…A pharmacokinetically guided phase I study of topotecan and etoposide phosphate was conducted in recurrent ovarian cancer. The scheduling of the topoisomerase…”
Get full text

Phase I trial of the selective mitochondrial toxin MKT 077 in chemo-resistant solid tumours by Propper, D. J., Braybrooke, J. P., Taylor, D. J., Lodi, R., Styles, P., Cramer, J. A., Collins, W. C. J., Levitt, N. C., Talbot, D. C., Ganesan, T. S., Harris, A. L.

“…Background: MKT 077 is a rhodacyanine dye analogue which preferentially accumulates in tumour cell mitochondria. It is cytotoxic to a range of tumours. In this…”
Get full text

Phase II study of exatecan mesylate (DX-8951f) as first line therapy for advanced non-small cell lung cancer by Braybrooke, J.P, Ranson, M, Manegold, C, Mattson, K, Thatcher, N, Cheverton, P, Sekiguchi, M, Suzuki, M, Oyama, R, Talbot, D.C

“…Background: Exatecan mesylate (DX-8951f) is a water soluble analogue of camptothecin that inhibits topoisomerase I. This multi-centre phase II study evaluated…”
Get full text

The effect of chemotherapy on health-related quality of life in mesothelioma: results from the SWAMP trial by Arnold, D T, Hooper, C E, Morley, A, White, P, Lyburn, I D, Searle, J, Darby, M, Hall, T, Hall, D, Rahman, N M, De Winton, E, Clive, A, Masani, V, Dangoor, A, Guglani, S, Jankowska, P, Lowndes, S A, Harvey, J E, Braybrooke, J P, Maskell, N A

“…Background: The effect of chemotherapy on health-related quality of life (HRQoL) in malignant pleural mesothelioma (MPM) is poorly understood…”
Get full text

Phase I and pharmacokinetic study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f ), using a weekly 30-minute intravenous infusion, in patients with advanced solid malignancies by Braybrooke, J. P., Boven, E., Bates, N. P., Ruijter, R., Dobbs, N., Cheverton, P. D., Pinedo, H. M., Talbot, D. C.

“…Background: The topoisomerase I inhibitor exatecan mesylate (DX-8951f ) is a water-soluble hexacyclic analogue of camptothecin that does not require enzymatic…”
Get full text

Phase II study of RC-160 (vapreotide), an octapeptide analogue of somatostatin, in the treatment of metastatic breast cancer by O'BYRNE, K. J, DOBBS, N, PROPPER, D. J, BRAYBROOKE, J. P, KOUKOURAKIS, M. I, MITCHELL, K, WOODHULL, J, TALBOT, D. C, SCHALLY, A. V, HARRIS, A. L

“…RC-160 (octastatin/vapreotide) is a potent octapeptide analogue of somatostatin with growth inhibitory activity in experimental tumours in vitro and in vivo,…”
Get full text

Phase II study of second-line therapy with DTIC, BCNU, cisplatin and tamoxifen (Dartmouth regimen) chemotherapy in patients with malignant melanoma previously treated with dacarbazine by PROPPER, D. J, BRAYBROOKE, J. P, LEVITT, N. C, O'BYRNE, K, CHRISTODOULOS, K, HAN, C, TALBOT, D. C, GANESAN, T. S, HARRIS, A. L

“…This study assessed response rates to combination dacarbazine (DTIC), BCNU (carmustine), cisplatin and tamoxifen (DBPT) chemotherapy in patients with…”
Get full text

Induction of thymidine phosphorylase as a pharmacodynamic end-point in patients with advanced carcinoma treated with 5-fluorouracil, folinic acid and interferon alpha by BRAYBROOKE, J. P, PROPPER, D. J, TALBOT, D. C, HARRIS, A. L, O'BYRNE, K. J, KOUKOURAKIS, M. I, PATTERSON, A. V, HOULBROOK, S, LOVE, S. D, VARCOE, S, TAYLOR, M, GANESAN, T. S

“…Thymidine phosphorylase (TP) is an essential enzyme for the biochemical activation of 5-fluorouracil (5-FU). Interferon upregulates TP in vivo, although the…”
Get full text

Phase I Study of the Novel Cyclic AMP (cAMP) Analogue 8-Chloro-cAMP in Patients with Cancer: Toxicity, Hormonal, and Immunological Effects by PROPPER, D. J, SAUNDERS, M. P, HARRIS, A. L, SALISBURY, A. J, LONG, L, O'BYRNE, K. J, BRAYBROOKE, J. P, DOWSETT, M, TAYLOR, M, TALBOT, D. C, GANESAN, T. S

“…The cyclic AMP (cAMP)-dependent protein kinase regulatory subunit RI is overexpressed in cancer cells. 8-Chloro-cAMP (8-Cl-cAMP) is an RII site-specific…”
Get full text

Phase II study of the oxygen saturation curve left shifting agent BW12C in combination with the hypoxia activated drug mitomycin C in advanced colorectal cancer by PROPPER, D. J, LEVITT, N. C, HARRIS, A. L, O'BYRNE, K, BRAYBROOKE, J. P, TALBOT, D. C, GANESAN, T. S, THOMPSON, C. H, RAJAGOPALAN, B, LITTLEWOOD, T. J, DIXON, R. M

“…BW12C (5-[2-formyl-3-hydroxypenoxyl] pentanoic acid) stabilizes oxyhaemoglobin, causing a reversible left-shift of the oxygen saturation curve (OSC) and tissue…”
Get full text